Liposarcoma - Pipeline Review, H2 2014 Summary Global Markets Direct's, 'Liposarcoma - Pipeline Review, H2 2014', provides an overview of the Liposarcoma's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Liposarcoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Liposarcoma and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Liposarcoma - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Liposarcoma and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Liposarcoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Liposarcoma pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Liposarcoma - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Liposarcoma pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents Table of Contents 2 List of Tables 4 List of Figures 4 Introduction 5 Global Markets Direct Report Coverage 5 Liposarcoma Overview 6 Therapeutics Development 7 Pipeline Products for Liposarcoma - Overview 7 Pipeline Products for Liposarcoma - Comparative Analysis 8 Liposarcoma - Therapeutics under Development by Companies 9 Liposarcoma - Therapeutics under Investigation by Universities/Institutes 10 Liposarcoma - Pipeline Products Glance 11 Clinical Stage Products 11 Early Stage Products 12 Liposarcoma - Products under Development by Companies 13 Liposarcoma - Products under Investigation by Universities/Institutes 14 Liposarcoma - Companies Involved in Therapeutics Development 15 AtheroNova Inc. 15 BioSpecifics Technologies Corp. 16 Karyopharm Therapeutics, Inc. 17 Novartis AG 18 Pfizer Inc. 19 Sanofi 20 Liposarcoma - Therapeutics Assessment 21 Assessment by Monotherapy Products 21 Assessment by Combination Products 22 Assessment by Target 23 Assessment by Mechanism of Action 25 Assessment by Route of Administration 27 Assessment by Molecule Type 29 Drug Profiles 31 AHRO-010 - Drug Profile 31 Product Description 31 Mechanism of Action 31 R&D Progress 31 collagenase clostridium histolyticum - Drug Profile 32 Product Description 32 Mechanism of Action 32 R&D Progress 32 everolimus - Drug Profile 36 Product Description 36 Mechanism of Action 36 R&D Progress 36 LEE-011 - Drug Profile 41 Product Description 41 Mechanism of Action 41 R&D Progress 41 palbociclib - Drug Profile 43 Product Description 43 Mechanism of Action 43 R&D Progress 43 SAR-405838 - Drug Profile 47 Product Description 47 Mechanism of Action 47 R&D Progress 47 selinexor - Drug Profile 48 Product Description 48 Mechanism of Action 48 R&D Progress 48 Thiazolidinediones + Retinoid X Receptor Selective Agonists - Drug Profile 51 Product Description 51 Mechanism of Action 51 R&D Progress 51 Liposarcoma - Recent Pipeline Updates 52 Liposarcoma - Product Development Milestones 76 Featured News & Press Releases 76 Jun 26, 2012: BioSpecifics Initiates XIAFLEX Phase II Trial For Human Lipomas 76 Appendix 77 Methodology 77 Coverage 77 Secondary Research 77 Primary Research 77 Expert Panel Validation 77 Contact Us 78 Disclaimer 78
List of Tables Number of Products under Development for Liposarcoma, H2 2014 7 Number of Products under Development for Liposarcoma - Comparative Analysis, H2 2014 8 Number of Products under Development by Companies, H2 2014 9 Number of Products under Investigation by Universities/Institutes, H2 2014 10 Comparative Analysis by Clinical Stage Development, H2 2014 11 Comparative Analysis by Early Stage Development, H2 2014 12 Products under Development by Companies, H2 2014 13 Products under Investigation by Universities/Institutes, H2 2014 14 Liposarcoma - Pipeline by AtheroNova Inc., H2 2014 15 Liposarcoma - Pipeline by BioSpecifics Technologies Corp., H2 2014 16 Liposarcoma - Pipeline by Karyopharm Therapeutics, Inc., H2 2014 17 Liposarcoma - Pipeline by Novartis AG, H2 2014 18 Liposarcoma - Pipeline by Pfizer Inc., H2 2014 19 Liposarcoma - Pipeline by Sanofi, H2 2014 20 Assessment by Monotherapy Products, H2 2014 21 Assessment by Combination Products, H2 2014 22 Number of Products by Stage and Target, H2 2014 24 Number of Products by Stage and Mechanism of Action, H2 2014 26 Number of Products by Stage and Route of Administration, H2 2014 28 Number of Products by Stage and Molecule Type, H2 2014 30 Liposarcoma Therapeutics - Recent Pipeline Updates, H2 2014 52
Our library has over 100000 reports on 1000s of topics
Over 100+ Fortune 500 companies rely on us
90,000+ people come to us for insights every month
Toll Free: 1-888-928-9744
Email: [email protected]
Speak to the report author to design an exclusive study to serve your research needs.
A testimonial for service excellence represented in the form of BBB "A" Accreditation.
Your personal and confidential information is safe and secure.